Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-10 EDT			5-day change	1st Jan Change
5.32 ^USD	-4.32%		-6.17%	-47.48%

05-09	Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating	MT
05-09	Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight	MT

Editas Medicine, Inc. Announces Bruce E. Eaton Will Step Down as Chief Technology Officer and Chief Business Officer, Effective January 2, 2024

October 10, 2023 at 04:05 pm

On October 3, 2023, Editas Medicine, Inc. and Bruce E. Eaton, Ph.D., Executive Vice President, Chief Technology Officer and Chief Business Officer of the Company, agreed that Dr. Eaton will step down as Chief Technology Officer and Chief Business Officer effective January 2, 2024.

Latest news about Editas Medicine, Inc.

Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating	05-09	MT
Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight	05-09	MT
Transcript : Editas Medicine, Inc., Q1 2024 Earnings Call, May 08, 2024	05-08
Editas Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration	05-01	MT
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration	05-01	CI
Transcript : Editas Medicine, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM	03-13
Barclays Adjusts Price Target on Editas Medicine to $11 From $10, Maintains Equal-Weight Rating	02-29	MT
Transcript : Editas Medicine, Inc., Q4 2023 Earnings Call, Feb 28, 2024	02-28
Editas Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Editas Medicine, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI
North American Morning Briefing : Stock Futures -2-	02-21	DJ
Transcript : Editas Medicine, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 04:30 PM	01-09
RBC Boosts Price Target on Editas Medicine to $11 From $8, Keeps Sector Perform Rating	01-03	MT
Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update	12-13	DJ
Editas Medicine Enters Licensing Deal With Vertex Pharmaceuticals for Cas9	12-13	MT
Editas Medicine Strikes License Deal With Vertex Pharmaceuticals	12-13	DJ
Editas Medicine and Vertex Pharmaceuticals Enter into Non-Exclusive License Agreement for Cas9	12-13	CI
Truist Adjusts Editas Medicine's Price Target to $20 From $15, Maintains Buy Rating	12-12	MT
Editas Medicine, Inc. Announces New EDIT-301 Safety And Efficacy Data In 17 Patients, Presented At The American Society Of Hematology Annual Meeting And In A Company-Sponsored Webinar	12-11	CI
Transcript : Editas Medicine, Inc. - Special Call	12-11
Transcript : Editas Medicine, Inc., Q3 2023 Earnings Call, Nov 03, 2023	11-03
Editas Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-03	CI
North American Morning Briefing : S&P 500 Futures -2-	11-03	DJ
Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored Webinar	11-02	CI

Chart Editas Medicine, Inc.

Duration

Period

More charts

Company Profile

Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Bank of America Securities Health Care Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Editas Medicine, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.32 USD

Average target price

15.13 USD

Spread / Average Target

+184.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EDITAS MEDICINE, INC.	-47.48%	438M
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research